WASHINGTON, D.C. - U.S. Senators Katie Britt (R-Ala.), Bill Cassidy (R-La.), and 90 Republican lawmakers recently filed another amicus brief in the Western District of Louisiana, supporting Louisiana's lawsuit to protect women and their unborn children from dangerous chemical abortion drugs. Earlier this year, Senator Britt joined Senator Cassidy and over 100 Republican lawmakers in filing an amicus brief arguing that mifepristone's in-person dispensing requirement be reinstated.

Just last week, Senator Britt questioned Acting Attorney General (AG) Todd Blanche at his nomination hearing, highlighting the dangerous lack of an in-person dispensing requirement for mifepristone and asking him to commit to taking action as AG.

"The rise of mail-order chemical abortion drugs endangers not only the lives of unborn babies, but also the health and safety of their mothers. Not to mention the horrifying stories we have heard from women who have been subject to coercion and deception by abusers," said Senator Britt. "My colleagues and I will continue to fight every day to protect women and children from this dangerous drug by ensuring the rule of law is upheld."

In October 2025, Attorney General Murrill filed a lawsuit on behalf of the State of Louisiana and Rosalie Markezich, a victim of Democrats' harmful decision to remove the in-person dispensing requirement for dangerous chemical abortion drugs. Because of President Biden's policy, Rosalie's boyfriend was able to order chemical abortion pills online from an abortionist in California and coerced her to take the drug to kill her unborn child.

"In-person dispensing requirements for chemical abortion drugs saves babies and protects women from coercion," said Senator Cassidy. "As a strong pro-life doctor, I will always defend the health and safety of mothers and unborn life. These commonsense safeguards must be reinstated immediately."

The Republican lawmakers argue that the Biden Administration violated federal law by removing the in-person dispensing requirement, and that these protections should be reinstated. Additionally, the amicus brief supports Attorney General Murrill's motion for preliminary relief, asking for a preliminary injunction ordering the Food and Drug Administration (FDA) to suspend or withdraw the 2023 Risk Evaluation and Mitigation Strategy (REMS) while the case proceeds.

The brief is also supported by Senators Jim Banks (R-Ind.), Marsha Blackburn (R-Tenn.), Ted Budd (R-N.C.), John Cornyn (R-Texas), Kevin Cramer (R-N.D.), Mike Crapo (R-Idaho), Ted Cruz (R-Texas), Steve Daines (R-Mont.), Josh Hawley (R-Mo.), John Hoeven (R-N.D.), Cindy Hyde-Smith (R-Miss.), James Lankford (R-Okla.), Roger Marshall, M.D. (R-Kan.), Rand Paul, M.D. (R-Ky.), Pete Ricketts (R-Neb.), Jim Risch (R-Idaho), Rick Scott (R-Fla.), Tim Sheehy (R-Mont.), and Tommy Tuberville (R-Ala.).

You can read the full amicus brief here.

Senator Britt is a strong champion for pro-life policies, previously joining her colleagues in urging the FDA to review the decision to approve a generic version of mifepristone. She recently joined Senator Marsha Blackburn (R-Tenn.) in introducing the Title X Abortion Provider Prohibition Act to ban federal Title X family-planning grants from going to any entity, such as Planned Parenthood, that performs abortions or funds abortion providers. She also joined Senator James Lankford (R-Okla.) in introducing the Born-Alive Abortion Survivors Protection Act to protect newborns who survive abortion attempts by requiring they receive care from health care practitioners. The Senator has an A+ grade from the Susan B. Anthony Pro-Life America scorecard for her work in protecting the lives of the most vulnerable.

###